Efficacy and safety of moxifloxacin in the outpatient treatment of exacerbations of chronic obstructive pulmonary disease

J. Minov (Skopje, FYROM (Macedonia)), J. Karadzinska-Bislimovska (Skopje, FYROM (Macedonia)), T. Petrova (Chicago, United States of America), K. Vasilevska (Skopje, FYROM (Macedonia)), S. Stoleski (Skopje, FYROM (Macedonia)), D. Mijakoski (Skopje, FYROM (Macedonia))

Source: International Congress 2018 – Pharmacological management of COPD
Session: Pharmacological management of COPD
Session type: Thematic Poster
Number: 768
Disease area: Airway diseases, Respiratory infections

Congress or journal article abstractE-poster

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
J. Minov (Skopje, FYROM (Macedonia)), J. Karadzinska-Bislimovska (Skopje, FYROM (Macedonia)), T. Petrova (Chicago, United States of America), K. Vasilevska (Skopje, FYROM (Macedonia)), S. Stoleski (Skopje, FYROM (Macedonia)), D. Mijakoski (Skopje, FYROM (Macedonia)). Efficacy and safety of moxifloxacin in the outpatient treatment of exacerbations of chronic obstructive pulmonary disease. 768

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you: